Health Canada Approves CAMBIA(R) for the Treatment of Acute Migraine – New Treatment Approved for Canadian Patients Suffering from Acute Migraine – PR Inside

CAMBIA® is expected to be launched in Canada in the second half of 2012. CAMBIA®, a novel, water-soluble, buffered diclofenac potassium powder engineered using Dynamic Buffering Technology(TM), a patented absorption-enhancing technology developed by a …

Leave a Reply

Your email address will not be published.

*